How often do you need the RSV shot: recommended schedule explained
Respiratory syncytial virus (RSV) is a common respiratory virus that can cause serious illness in infants, older adults, and people with certain medical conditions. Over the past few years, new preventive tools—vaccines for older adults and pregnant people, plus long-acting monoclonal antibodies for infants—have changed how clinicians think about RSV prevention. One of the most common questions is how often someone needs an RSV shot or dose to maintain protection. Understanding the typical dosing strategies and the differences between product types (vaccine versus monoclonal antibody) will help you plan care for yourself or a family member, but specific timing and repeat-dose needs depend on age, health status, and evolving public-health guidance.
How often should older adults get the RSV vaccine?
For adults, particularly those aged 60 and older or adults with chronic heart or lung disease, RSV vaccination has become an option to reduce the risk of severe respiratory illness. The currently available adult RSV vaccines are administered as a single dose at the time of vaccination. Whether that single dose should be repeated annually—similar to seasonal influenza vaccines—is an area of active study and policy discussion. Many public health authorities and clinicians are treating the RSV vaccine as a seasonal prevention tool during periods of RSV circulation, and they may recommend a repeat dose in subsequent RSV seasons for those at higher risk. If you are an older adult or care for one, discuss timing and repeat-dose considerations with your clinician, who can factor in local RSV activity, underlying conditions, and vaccine availability.
What is the recommended schedule for infants and young children?
Infants and some young children are at highest risk of hospitalization from RSV. Instead of a traditional vaccine for infants, long-acting monoclonal antibody injections (for example, nirsevimab) are used to provide passive immunity during the RSV season. These injections are typically given as a single dose before or at the start of the RSV season to protect the child for several months. In infants born during or just before an RSV season, one dose can be sufficient for that season; infants who remain at risk in a subsequent RSV season may receive another dose the following season. Routine pediatric immunization schedules do not currently include an infant RSV vaccine, so follow-up with your pediatrician is important for seasonal planning and any catch-up doses.
When is maternal RSV vaccination recommended and how often?
Vaccinating pregnant people during a specified window of pregnancy is another strategy to protect newborns during their first months. Maternal RSV vaccination is given as a single dose during pregnancy—typically in the late second or third trimester—so that antibodies transfer to the fetus and provide passive protection after birth. That dose is timed to optimize antibody levels when the newborn’s risk of severe RSV is highest. Maternal vaccines are given once per pregnancy for that purpose; routine repeat dosing in the same pregnancy is not recommended. If you are pregnant or planning pregnancy, talk with your obstetric provider about the optimal timing to maximize infant protection.
Who might need additional doses or boosters, and what are the considerations?
Certain people—those who are immunocompromised, have significant cardiopulmonary disease, or are in long-term care settings—may warrant individualized planning about RSV prevention. Because long-term durability of protection from available products varies and evidence about booster timing continues to emerge, clinicians may recommend repeat doses across seasons for high-risk individuals. Decisions about boosters take into account age, underlying conditions, prior RSV prevention history (vaccine or monoclonal antibody), and local RSV activity. Safety monitoring and real-world effectiveness studies are ongoing, so guidance can change as more data become available.
Quick-reference schedule: who gets what and how often
Below is a simplified table to summarize common scenarios. This is a general guide; individual recommendations may differ based on health status and updated public-health guidance.
| Population | Product type | Typical dosing | Repeat/booster guidance |
|---|---|---|---|
| Adults 60+ (or high-risk adults) | RSV vaccine | Single dose | May be considered in subsequent RSV seasons for high-risk people; guidance evolving |
| Pregnant people | Maternal RSV vaccine | Single dose during recommended pregnancy window | One dose per pregnancy; not repeated in same pregnancy |
| Infants and young children | Long-acting monoclonal antibody (e.g., nirsevimab) | Single dose before/during RSV season | May receive another dose in a subsequent RSV season if still age-eligible |
| Immunocompromised or medically complex individuals | Vaccine or tailored prophylaxis | Individualized by clinician | Often considered for repeat seasonal protection; consult specialist |
Because RSV prevention options include both active vaccination and passive antibody protection, the term “RSV shot” can mean different products for different age groups. That distinction affects how often doses are needed: vaccines stimulate the recipient’s immune response, while monoclonal antibodies provide immediate but temporary antibodies.
Decisions about timing and repeat doses for RSV prevention are best made with a healthcare provider who can interpret current public-health guidance, local RSV seasonality, and individual risk factors. Staying informed about updated recommendations from public-health agencies and discussing vaccine or prophylaxis options during routine care visits will help ensure appropriate protection.
Medical disclaimer: This article provides general information and does not replace personalized medical advice. For specific recommendations about RSV vaccination or monoclonal antibody prophylaxis, consult your healthcare provider or local public-health authority, as guidance and product availability may change.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
